about
Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotionHighlights lecture EANM 2015: the search for nuclear medicine's superheroesHuman Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-ImagingPositron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphomaAurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.Is the image quality of I-124-PET impaired by an automatic correction of prompt gammas?Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology.Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy?In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy.Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors.Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.Positron detection for the intraoperative localisation of cancer deposits[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experienceCombined [(18)F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice.Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy.Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapySPECT/CT.Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values.Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.PET tracers in musculoskeletal disease beyond FDG.Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.Alternative PET Tracers in Musculoskeletal Disease.Improved synthesis of [¹⁸F]FS-PTAD as a new tyrosine-specific prosthetic group for radiofluorination of biomolecules.Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: correlation with in vivo 17.6T MRI.PET imaging with [⁶⁸Ga]NOTA-RGD for prostate cancer: a comparative study with [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluoroethylcholine.FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy?[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CTImaging proliferation to monitor early response of lymphoma to cytotoxic treatment.Synthesis and biodistribution of 3'-fluoro-5-[(131)I]iodo-2'-deoxyuridine: a comparative study of [(131)I]FLIdU and [(18)F]FLT.
P50
Q24644807-31CAC560-FF04-4AEE-9682-BB23CC476CF5Q26745705-3016F15B-87EB-4768-875D-38642098D7FAQ28553420-89958CEA-53DC-4606-BC1D-B22AA328B87FQ33706877-01F77703-45F1-485C-B30F-26E17D11254CQ34124945-1D17B2C5-7BD5-4270-9176-32E4C17DDA84Q34981083-79078583-AC38-419B-BFC3-0EEE28C60317Q35078496-6A35CC76-115A-4BB3-8B1B-8AE6C536DF51Q35217230-314478B2-C9DD-4972-BB18-F096499330F8Q35483867-57ED44CA-DE9A-4B6B-8DDD-FF0EBC66734EQ35877119-07457834-958E-49AE-A15A-7A2A411BFB30Q36011116-5BB736D6-BDA6-4A08-A6B0-67F7E726C37EQ36226361-47BDA4F5-AECC-4E90-931C-0C8BBB6E7208Q36329223-9487DC5F-177E-4B0A-AC52-FBEAF582BF32Q36715057-E9F9E434-BBCF-4BC8-ACC1-65A27B080222Q36925038-0E2C60F9-A417-4C24-BC2D-4F2529F236DAQ36962582-5A0F9737-6804-4CF7-A2E2-CFAC195674BFQ36980969-48BD81B5-4349-497B-91A5-1404DAE7004FQ37010592-A062B268-6DCD-44DD-B8CD-2CB382350971Q37016783-A96DCC41-4B2E-482E-AA5A-48DBA866043EQ37190242-120D1AEE-EE47-49B2-8853-14DC908FE4FFQ37214430-85715843-AAB8-446F-AA65-3B3CA443B440Q37218591-5A6D48CB-E1FF-4D0D-8D66-26ECAC6FD82FQ37314625-1C4DA44D-8321-4701-AEBC-7F1EB26EFD49Q37541868-26A353B9-0FE4-4DEA-A834-B6962A999DF7Q37641220-ABCCED73-AD18-4979-941D-8AB88D00C379Q38203194-69AAAD7D-59AE-4FA2-95DC-2BBD970669ABQ38230240-E892178B-6C1B-42C5-8C0C-780F7D56F5FEQ38230269-3500E2B4-1CC6-4F28-85D4-513146030BC5Q38762963-D564A0A7-0BEF-4FD2-9D49-0D201A8F5088Q38804450-4E57149F-BCDF-4ECC-8064-6184FBAB8D52Q38829194-4660369D-712B-4D12-8A1A-0A92D5EDBE00Q38854899-3E484836-84BC-445D-BA81-13F7C945755BQ38987849-8248FA8E-F510-402B-8C13-DD247BF1E6FBQ39005621-3E53DDB1-AA53-47DA-A7E1-E16A868D8F55Q39300569-8AF50ECC-7F94-4BAD-9E1D-27DD078FB1F2Q39361816-0C121168-59F9-4AE6-A0F3-E75E4F8B71DDQ39698461-3593F2E0-F9FC-4D79-BA61-7DC763D18CD2Q39922053-7B0A076C-83A2-4D48-8B4F-B656F2CF75A1Q39950405-F3D491FC-91D4-4E9B-B118-CD19E61D2A0EQ40154735-2FFD8B76-E505-4F2F-A203-5517CAE09653
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Andreas K. Buck
@ast
Andreas K. Buck
@de
Andreas K. Buck
@en
Andreas K. Buck
@es
Andreas K. Buck
@nl
Andreas K. Buck
@sq
type
label
Andreas K. Buck
@ast
Andreas K. Buck
@de
Andreas K. Buck
@en
Andreas K. Buck
@es
Andreas K. Buck
@nl
Andreas K. Buck
@sq
altLabel
Andreas Buck
@en
prefLabel
Andreas K. Buck
@ast
Andreas K. Buck
@de
Andreas K. Buck
@en
Andreas K. Buck
@es
Andreas K. Buck
@nl
Andreas K. Buck
@sq
P214
P227
P1153
55549623800
56890614400
P21
P214
P227
P31
P496
0000-0002-6447-0613
P569
1970-01-01T00:00:00Z
P734
P735
P7859
viaf-47599245